Revenue
2025
Aardvark Therapeutics, Inc. (AARD)
Price—Loading quote
Net income
2024
2025
Free cash flow
2024
2025
Total cash / debt
CashTotal debt
2023
2024
2025
Financial statements
| 2025 | 2024 | |
|---|---|---|
| Revenue | $0 | — |
| Research & development | $48.9M | $17.4M |
| Operating expenses | $62.7M | $22.8M |
| Operating income | −$62.7M | −$22.8M |
| EBITDAderived | −$62.7M | −$22.8M |
| Net income | −$57.6M | −$20.6M |
| Basic EPSper diluted share | -$2.93 | -$5.15 |
| Diluted EPSper diluted share | -$2.93 | -$5.15 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 11, 2025Form 4 | Sun NelsonChief Financial Officer | BuyCommon Stock | 3.0K | $14.40 | $43.2K | 108.5K |
| Dec 11, 2025Form 4 | Lee Tien-LiChief Executive Officer | BuyCommon Stock | 7.0K | $14.49 | $101.4K | 1.55M |
| Sep 15, 2025Form 4 | Lee Tien-LiChief Executive Officer | BuyCommon Stock | 3.5K | $9.94 | $34.8K | 1.54M |
| Sep 15, 2025Form 4 | Lee Tien-LiChief Executive Officer | BuyCommon Stock | 6.5K | $9.51 | $61.8K | 1.54M |
| Sep 12, 2025Form 4 | Lee Tien-LiChief Executive Officer | BuyCommon Stock | 5.0K | $8.50 | $42.5K | 1.53M |